Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(11%)
Results Posted
100%(7 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_3
2
22%
Ph phase_2
1
11%
Ph phase_4
5
56%

Phase Distribution

0

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
2(25.0%)
Phase 4Post-market surveillance
5(62.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(7)
Terminated(1)

Detailed Status

Completed7
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (12.5%)
Phase 32 (25.0%)
Phase 45 (62.5%)

Trials by Status

completed778%
recruiting111%
terminated111%

Recent Activity

1 active trials
Showing 5 of 9
completedphase_4

China Post-marketing Surveillance (PMS) Study of Fabrazyme®

NCT05054387
terminatedphase_4

Study of the Effects of Fabrazyme Treatment on Lactation and Infants

NCT00230607
recruiting

Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

NCT05698901
completedphase_3

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

NCT02795676
completedphase_2

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

NCT01196871
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05054387Phase 4

China Post-marketing Surveillance (PMS) Study of Fabrazyme®

Completed
NCT00230607Phase 4

Study of the Effects of Fabrazyme Treatment on Lactation and Infants

Terminated
NCT05698901

Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

Recruiting
NCT02795676Phase 3

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

Completed
NCT01196871Phase 2

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

Completed
NCT00701415Phase 3

A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms

Completed
NCT00140621Phase 4

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

Completed
NCT00081497Phase 4

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Completed
NCT01650779Phase 4

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9